New Experimental Therapy For Alzheimer’s Agitation Shows Promise

New Experimental Therapy For Alzheimer’s Agitation Shows Promise
agitation in Alzheimer's diseaseAvanir Pharmaceuticals Inc. reported today new, positive results for their leading drug, AVP-923, designed to treat agitation in Alzheimer's disease patients. The results will be presented at the American Neurological Association's (ANA) 2014 Annual Meeting in Baltimore, MD, October 12-14, 2014. Joao Siffert, MD, chief medical officer at Avanir, said, "With no FDA-approved drugs for the treatment of agitation in Alzheimer's disea
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *